At the heart of public health are physicians, who dedicate their lives to assuring that patients suffering from a myriad of disease states receive appropriate healthcare. We at ViroPharma are in turn dedicated to physician education, and bringing new products to them.
Since ViroPharma’s acquisition of Vancocin in 2004, rather than developing a sales organization to promote the drug, we made the business decision to focus our attention on physician education and ensuring patient safety. Our objectives today are clear, and include assisting physicians in their work to assure the safety and appropriate treatment of patients with severe CDAD.
Our focus will remain on physician education, but our broader ambitions also include developing new treatments for other diseases, including those caused by cytomegalovirus and hepatitis C, to improve the lives of their patients.
Learn more about out therapeutic areas, gastroenterology and hospital/transplant medicine